Sarcopenia Physical Activity and Metabolomic

NCT05199207 | Completed

• 1 other identifier: 20-AOI-11
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Muscle failure (sarcopenia or dynapenia) is a factor of frailty and therefore, ultimately, of loss of autonomy in the elderly. Currently, no biomarker of muscle failure has a high sensitivity, specificity and positive predictive value. Several results, although preliminary, suggest that metabolomics could facilitate the early identification of frail patients, allowing the implementation of primary prevention strategies. Untargeted high-resolution metabolomics analysis would identify discriminative biomarkers and biological mechanisms associated with frailty. Finally, the hypothesis that metabolic signatures can be identified as risk factors for the development of age-related dynapenia should be tested in a longitudinal design.

Conditions

Sarcopenia

Outcome Measures

Primary Outcomes (1)

• Different metabolomic signature (The amino acid composition) between the sarcopenic group and the control group

  Change in the amino acid composition (metabolomic signature) at Day 0 between the sarcopenic group and the control group

  at Day 0

Secondary Outcomes (1)

• Change in the amino acid composition (metabolomic signature) after 3 month of physical activity

  between Day 0 and Month 3

Study Arms (2)

Sarcopenic patient

EXPERIMENTAL

Patient with sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)

Behavioral: Physical activity programm

Non sarcopenic patient

ACTIVE COMPARATOR

Patient without sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)

Behavioral: Physical activity programm

Interventions

Physical activity programm BEHAVIORAL

adapted physical activity during 3 month

Non sarcopenic patient; Sarcopenic patient

Eligibility Criteria

• Age: 65 Months+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age greater than or equal to 65 years;
• Patient affiliated or beneficiary of a social security plan;
• Patient having signed a prior informed consent

You may not qualify if:

• presence of a physical or cognitive pathology preventing the performance of the physical activity protocol during 3 months
• Patient with legal protection

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (1)

CHU de Nice

Nice, 06000, France

Location

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Emeline MICHEL, MD

  Nice University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2021
• First Posted: January 20, 2022
• Study Start: January 11, 2022
• Primary Completion: April 22, 2022
• Study Completion: July 5, 2022
• Last Updated: July 13, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)